王勝鵬
下載導師簡歷CV
Section 1: Personal Particulars
王勝鵬
WANG Shengpeng
Associate Professor
+853 2884 1358
+853 88228559
swang@um.edu.mo
澳門大學
澳門大學-中藥機制與質量全國重點實驗室
Assistant Director of State Key Laboratory of Mechanism and Quality of Chinese Medicine & Deputy Director of Macao Centre for Research and Development in Chinese Medicine
https://sklmqcm.um.edu.mo/sheng-peng-wang/
Research Project provided for Macao Youth Scholars Program:
中藥多糖構效關係研究
Structure-activity relationship of Chinese medicine polysaccharides
1008 中药学
0701 数学,0706 大气科学,0809 电子科学与技术,0810 信息与通信工程,0812 计算机科学与技术,0831 生物医学工程,0836 生物工程,1001 基础医学,1005 中医学,1006 中西医结合,1007 药学,1008 中药学,1010 医学技术
Experienced in the preparation and characterization of polysaccharides from Chinese medicine, proficient in both in vitro and in vivo pharmacological efficacy studies, and adept at applying multi-omics technologies—such as microbiomics and metabolomics
PhD
Major Accomplishments:
Focused on the bioactive constituents of Chinese medicine (CM) and the discovery and development of innovative CM-based therapeutics.
Published over 200 peer-reviewed, SCI-indexed papers with more than 11,000 total citations (h-index: 55).
Served as Principal Investigator on more than 10 major research projects, including the Macao Key R&D Program.
Led the development of three classical CM prescriptions, one hospital-formulated preparation, and eight international standards for CM, advancing the global standardization and scientific validation of CM.
Honors and Awards:
(1) National ‘Qi-Huang’ Young Scholar 青年岐黃學者, The State Administration of Traditional Chinese Medicine, 2025.
(2) Highly Cited Researcher (Cross field), Clarivate, 2023.
(3) World’s Top 2% Scientists (Career and single-year impact), 2020-2025.
(4) Gold award, 47th International Exhibition of Inventions of Geneva, Switzerland, 2019.
(5) International Award for Contribution to Chinese Medicine-1st Grade Achievement Award in Medical Science, China, 2020.
Patents:
(1) Wang SP, Zhang GH. A Natural PXR agonist and its Application in Colitis. China, CN119405649A, 2025.
(2) Wang SP, Xiao YQ. Application of Dubosiella newyorkensis for inflammatory bowel disease. China, CN116747244A. 2023.
(3) Wang YT, LI P, Yu H, Wang CM, Wang SP, Zhang JM. Development of solid-liquid capsules for Chinese medicine. China, CN106963742A. 2016.
Section 2: Research Interests and Grants
Structure-activity relationship of natural polysaccharides and Development of novel products of Chinese medicine
11
10
4
(1) Title: University of Macau-Tianjin Pharmaceutical Da Ren Tang Group Joint Laboratory of Chinese medicine innovation; Source: Tianjin Pharmaceutical Da Ren Tang Group; No.: EF2023-00213-ICMS; Amount: MOP 6,780,000; Duration: 2023/08/24-2028/08/23 (5 years)
(2) Title: Preclinical Study of Class 1 Chinese Medicine New Drug “Nuangong Tiaojing Granules” (National TCM Master proved prescription); Source: FDCT; No.: 0045/2024/AGJ; Amount: MOP 1,040,000; Duration: 2024/10/31-2026/10/30 (5 years)
(3) Title: Development of compound preparation of ancient classical prescription Banxia Xiexin Decoction and registration in Macao; Source: Zhangzhou Pien Tze Huang Pharmaceutical Co. Ltd.; No.: CP-027-2022; Amount: MOP 5,150,000; Duration: 21/09/2022-30/09/2027 (5 years)
(2) Title: Preclinical Study of Class 1 Chinese Medicine New Drug “Nuangong Tiaojing Granules” (National TCM Master proved prescription); Source: FDCT; No.: 0045/2024/AGJ; Amount: MOP 1,040,000; Duration: 2024/10/31-2026/10/30 (5 years)
(3) Title: Development of compound preparation of ancient classical prescription Banxia Xiexin Decoction and registration in Macao; Source: Zhangzhou Pien Tze Huang Pharmaceutical Co. Ltd.; No.: CP-027-2022; Amount: MOP 5,150,000; Duration: 21/09/2022-30/09/2027 (5 years)